TAMPA, FL / ACCESSWIRE / May 5, 2023 / TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the first quarter 2023, after market close on May 15, 2023. Please note that this is a revised date from the original reporting date of May 8, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
In addition, management will host a conference call on Monday, May 15, 2023, at 6:00 p.m. Eastern time to discuss TRxADE HEALTH's first quarter 2023 financial results. The call will conclude with a Q&A from participants. To participate, please use the following information:
Q1 2023 Conference Call and Webcast
Date: Monday, May 15, 2023
Time: 6:00 p.m. Eastern time
U.S. Dial-in: 1-877-425-9470
International Dial-in: 1-201-389-0878
Webcast: https://callme.viavid.com/viavid/?callme=true&passcode=13711397&h=true&info=company&r=true&B=6 - Participants can use Guest dial-in #s above and be answered by an operator
Please dial in at least 10 minutes before the start of the call to ensure timely participation.
A playback of the call will be available through June 15, 2023. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally and enter replay pin number 13738429. A webcast will also be available for 30 days on the IR section of the Trxade Group website or by clicking the webcast link above.
About TRxADE HEALTH, INC.
TRxADE HEALTH (NASDAQ:MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving approximately 14,500+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services. For more information on TRxADE HEALTH, please visit the Company's IR website at investors.trxadegroup.com.
Investor Relations:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors.trxadegroup.com
| Last Trade: | US$8.00 |
| Daily Volume: | 7,269 |
July 26, 2024 October 12, 2023 August 22, 2023 August 03, 2023 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
